Matei Nathanael, Camara Justin, Zhang John H
Department of Ophthalmology, University of Southern California, Los Angeles, CA, United States.
Department of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA, United States.
Front Neurol. 2021 Jan 22;11:582605. doi: 10.3389/fneur.2020.582605. eCollection 2020.
Although many patients do not receive reperfusion therapy because of delayed presentation and/or severity and location of infarct, new reperfusion approaches are expanding the window of intervention. Novel application of neuroprotective agents in combination with the latest methods of reperfusion provide a path to improved stroke intervention outcomes. We examine why neuroprotective agents have failed to translate to the clinic and provide suggestions for new approaches. New developments in recanalization therapy in combination with therapeutics evaluated in parallel animal models of disease will allow for novel, intra-arterial deployment of therapeutic agents over a vastly expanded therapeutic time window and with greater likelihood success. Although the field of neuronal, endothelial, and glial protective therapies has seen numerous large trials, the application of therapies in the context of newly developed reperfusion strategies is still in its infancy. Given modern imaging developments, evaluation of the penumbra will likely play a larger role in the evolving management of stroke. Increasingly more patients will be screened with neuroimaging to identify patients with adequate collateral blood supply allowing for delayed rescue of the penumbra. These patients will be ideal candidates for therapies such as reperfusion dependent therapeutic agents that pair optimally with cutting-edge reperfusion techniques.
尽管许多患者由于就诊延迟和/或梗死的严重程度及部位而未接受再灌注治疗,但新的再灌注方法正在扩大干预窗口。神经保护剂的新应用与最新的再灌注方法相结合,为改善中风干预结果提供了一条途径。我们探讨了神经保护剂未能转化为临床应用的原因,并为新方法提供了建议。再灌注治疗的新进展与在平行疾病动物模型中评估的治疗方法相结合,将允许在大大扩展的治疗时间窗口内以新的方式经动脉部署治疗剂,且成功可能性更大。尽管神经元、内皮细胞和神经胶质保护疗法领域已经进行了大量大型试验,但在新开发的再灌注策略背景下应用这些疗法仍处于起步阶段。鉴于现代影像学的发展,半暗带的评估可能在不断发展的中风管理中发挥更大作用。越来越多的患者将接受神经影像学筛查,以识别具有足够侧支血供的患者,从而实现半暗带的延迟挽救。这些患者将是依赖再灌注的治疗剂等疗法的理想候选者,这些疗法可与前沿再灌注技术实现最佳配合。